Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.48 |
| ▸ | HTR2B | P41595 | 10/20 | 0.48 |
| ▸ | HTR2C | P28335 | 9/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135206 | 0.94 | TP53 (0.45) | HTR2AHTR2BHTR2CTP53SMN1; SMN2 | |
| SCHEMBL5135482 | 0.94 | HTR2A (0.43) | HTR2AHTR2BHTR2CTP53SMN1; SMN2 | |
| SCHEMBL5137546 | 0.93 | HTR2A (0.49) | HTR2AHTR2BHTR2CTP53SMN1; SMN2 | |
| SCHEMBL5136199 | 0.92 | HTR2A (0.47) | HTR2AHTR2BHTR2CTP53SMN1; SMN2 | |
| SCHEMBL5136838 | 0.92 | HTR2A (0.46) | HTR2AHTR2BHTR2CTP53SMN1; SMN2 | |
| SCHEMBL5136215 | 0.91 | HTR2A (0.57) | HTR2AHTR2BHTR2CTP53SMN1; SMN2 | |
| SCHEMBL5135658 | 0.89 | HTR2A (0.52) | HTR2AHTR2BHTR2CTP53SMN1; SMN2 | |
| SCHEMBL5135886 | 0.89 | C5AR1 (0.42) | HTR2AHTR2BHTR2CTP53SMN1; SMN2 | |
| SCHEMBL5137303 | 0.89 | TP53 (0.51) | HTR2AHTR2BHTR2CTP53SMN1; SMN2 | |
| SCHEMBL5136744 | 0.88 | C5AR1 (0.47) | HTR2AHTR2BHTR2CTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |